Physical Function During ARSI Treatment

Korábbi kezelés

• Prior ARSI treatment
• Current chemotherapy
• Intention to leave the region prior to completion of study

Más betegség

• History of bone fractures or musculoskeletal injuries
• Neurological conditions that affect balance and/or muscle strength
• Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent

• Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
• Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
• Age ≥ 18 years at the time of consent.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Diagnosis of metastatic disease from prostate cancer, or recurrent disease following definitive local therapy of prostate cancer, as assessed by their clinician
• Initiation of an ARSI (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide) for mPC with concurrent androgen deprivation therapy (ADT).
• Availability to begin baseline testing within 8 weeks of ARSI treatment initiation.
• Physician clearance to perform physical assessments.
• Ability to speak and read English.